Nan Dai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nan Dai has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Dong Wang
Department of Oncology, Chongqing University Qianjiang Hospital, Chongqing, People’s Republic of China
2 shared publications Mengxia Li
Department of Oncology, Daping Hospital, Army Medical University, Chongqing 400042, China
2 shared publications- Bo Yang
Cancer Center, Daping Hospital and Army Medical Center of PLA, Army Medical University, Chongqing, People’s Republic of China
1 shared publication Chengxiong Xu
Cancer Center, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing 400038, P.R. China
1 shared publicationChengyuan Qian
Department of Oncology, Daping Hospital, Army Medical University, Chongqing 400042, China
1 shared publicationDan Jian
Department of Oncology, Daping Hospital, Army Medical University, Chongqing 400042, China
1 shared publication
Latest Publications
- 5 February 2023
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 25 (6) , 1767-1778
Frequently mutated genes in predicting the relapse of stage I lung adenocarcinoma
Purpose Approximately, 45–65% stage I non-small cell lung cancer (NSCLC) patients with surgical resection relapse within 5 years. Therefore, it is urgent to identify the predictors involved in the relapse of stage I NSCLC. Methods/patients Targeted sequencing was used to examine the mutation of tumor tissues and matched adjacent normal tissues from 35 patients with stage I lung adenocarcinoma (LUAD). Then, tissue microarrays containing tumor tissues from 149 stage I LUAD patients were used to assess protein expression of frequently mutated genes by immunohistochemistry. COX regression model was used to evaluate the impacts of frequently mutated genes and their protein expression on relapse-free survival (RFS) in stage I LUAD. Results and conclusions Three hundred and twenty-nine non-synonymous somatic variants were identified in 161 genes among these 35 patients. EGFR, TP53, LRP1B, RBM10, KRAS, NTRK3, RB1, ALK, APC, FAT2, KEAP1, MED12 and MLL3 were described as frequently mutated genes with prevalence more than 10%. Patients harboring KRAS mutation had more relapse in 1 year after surgical resection. For the expression of these frequently mutated genes in 149 stage I patients, multivariate Cox regression analyses showed that the expression of RBM10 was positively associated with RFS in all patients (HR 0.40, 95% CI 0.15–1.0, p = 0.052), and the expression of APC was negative associated with RFS in patients with EGFR mutations (HR 3.10, 95% CI 1.54–6.26, p = 0.002). Stage I LUAD patients with KRAS mutation or low RBM10 expression are inclined to receive more positive intervention rather than just disease surveillance.
- 5 February 2023
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 25 (6) , 1767-1778
Frequently mutated genes in predicting the relapse of stage I lung adenocarcinoma
Purpose Approximately, 45–65% stage I non-small cell lung cancer (NSCLC) patients with surgical resection relapse within 5 years. Therefore, it is urgent to identify the predictors involved in the relapse of stage I NSCLC. Methods/patients Targeted sequencing was used to examine the mutation of tumor tissues and matched adjacent normal tissues from 35 patients with stage I lung adenocarcinoma (LUAD). Then, tissue microarrays containing tumor tissues from 149 stage I LUAD patients were used to assess protein expression of frequently mutated genes by immunohistochemistry. COX regression model was used to evaluate the impacts of frequently mutated genes and their protein expression on relapse-free survival (RFS) in stage I LUAD. Results and conclusions Three hundred and twenty-nine non-synonymous somatic variants were identified in 161 genes among these 35 patients. EGFR, TP53, LRP1B, RBM10, KRAS, NTRK3, RB1, ALK, APC, FAT2, KEAP1, MED12 and MLL3 were described as frequently mutated genes with prevalence more than 10%. Patients harboring KRAS mutation had more relapse in 1 year after surgical resection. For the expression of these frequently mutated genes in 149 stage I patients, multivariate Cox regression analyses showed that the expression of RBM10 was positively associated with RFS in all patients (HR 0.40, 95% CI 0.15–1.0, p = 0.052), and the expression of APC was negative associated with RFS in patients with EGFR mutations (HR 3.10, 95% CI 1.54–6.26, p = 0.002). Stage I LUAD patients with KRAS mutation or low RBM10 expression are inclined to receive more positive intervention rather than just disease surveillance.
- 8 August 2022
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 61, 152024
Next generation sequencing targeted detection of somatic mutations in patients with mucinous adenocarcinoma of the appendix
- 8 August 2022
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 61, 152024
Next generation sequencing targeted detection of somatic mutations in patients with mucinous adenocarcinoma of the appendix
- Open Access
- 4 September 2020
- Published by Spandidos Publications in Oncology Reports
- Vol. 44 (5) , 2165-2173
Downregulation of exosomal miR‑1273a increases cisplatin resistance of non‑small cell lung cancer by upregulating the expression of syndecan binding protein
Resistance to platinum‑based drugs, such as cisplatin (CDDP), has been one of the major factors adversely affecting the clinical prognosis of patients with advanced non‑small cell lung cancer (NSCLC). While it has been demonstrated that dysregulation of microRNAs (miRNAs) may contribute to cisplatin resistance in NSCLC, the underlying mechanisms remain largely unclear. In the present study, the effect of exosomal miR‑1273a on cisplatin sensitivity of NSCLC was investigated. Microarray analysis was conducted to analyze the miRNA expression profiles in exosomes isolated from A549 cells treated with or without CDDP, and miR‑1273a was found to be the most prominently downregulated miRNA in CDDP‑treated exosomes. Overexpression of miR‑1273a significantly increased the cytotoxicity of CDDP and induced apoptosis in A549 cells. Syndecan binding protein (SDCBP) was predicted to be a direct target of miR‑1273a by bioinformatics and was found to be downregulated by miR‑1273a in A549 cells. Furthermore, decreased plasma exosomal miR‑1273a and increased plasma SDCBP levels were found to be associated with worse therapeutic outcomes of patients with advanced NSCLC receiving platinum‑based chemotherapy. These findings suggest that miR‑1273a is closely associated with the development of cisplatin resistance and may serve as a potential prognostic biomarker and therapeutic target for NSCLC.
- 4 September 2020
- Published by Spandidos Publications in Oncology Reports
- Vol. 44 (5) , 2165-2173
Open AccessDownregulation of exosomal miR‑1273a increases cisplatin resistance of non‑small cell lung cancer by upregulating the expression of syndecan binding protein
Resistance to platinum‑based drugs, such as cisplatin (CDDP), has been one of the major factors adversely affecting the clinical prognosis of patients with advanced non‑small cell lung cancer (NSCLC). While it has been demonstrated that dysregulation of microRNAs (miRNAs) may contribute to cisplatin resistance in NSCLC, the underlying mechanisms remain largely unclear. In the present study, the effect of exosomal miR‑1273a on cisplatin sensitivity of NSCLC was investigated. Microarray analysis was conducted to analyze the miRNA expression profiles in exosomes isolated from A549 cells treated with or without CDDP, and miR‑1273a was found to be the most prominently downregulated miRNA in CDDP‑treated exosomes. Overexpression of miR‑1273a significantly increased the cytotoxicity of CDDP and induced apoptosis in A549 cells. Syndecan binding protein (SDCBP) was predicted to be a direct target of miR‑1273a by bioinformatics and was found to be downregulated by miR‑1273a in A549 cells. Furthermore, decreased plasma exosomal miR‑1273a and increased plasma SDCBP levels were found to be associated with worse therapeutic outcomes of patients with advanced NSCLC receiving platinum‑based chemotherapy. These findings suggest that miR‑1273a is closely associated with the development of cisplatin resistance and may serve as a potential prognostic biomarker and therapeutic target for NSCLC.